Tekla Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Tekla Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-233,612	Closed	-$1.56M	–	201
2020 Q4	$1.56M	Hold	233,612	–	–	0.05%	166
2020 Q3	$1.18M	Hold	233,612	–	–	0.04%	175
2020 Q2	$1.89M	Sell	233,612 -332,454	-59%	-$2.93M	0.07%	164
2020 Q1	$4.5M	Sell	566,066 -248,522	-31%	-$1.91M	0.2%	91
2019 Q4	$6.15M	Hold	814,588	–	–	0.23%	90
2019 Q3	$3.39M	Hold	814,588	–	–	0.15%	107
2019 Q2	$2.35M	Hold	814,588	–	–	0.1%	126
2019 Q1	$1.17M	Hold	814,588	–	–	0.05%	153
2018 Q4	$2.1M	Hold	814,588	–	–	0.09%	126
2018 Q3	$3.58M	Hold	814,588	–	–	0.13%	114
2018 Q2	$4.99M	Hold	814,588	–	–	0.19%	91
2018 Q1	$5.94M	Buy	814,588 +190,300	+30%	+$1.67M	0.23%	86
2017 Q4	$5.12M	Hold	624,288	–	–	0.2%	90
2017 Q3	$6.55M	Hold	624,288	–	–	0.23%	74
2017 Q2	$6.89M	Hold	624,288	–	–	0.26%	74
2017 Q1	$6.04M	Hold	624,288	–	–	0.23%	77
2016 Q4	$6.49M	Hold	624,288	–	–	0.28%	68
2016 Q3	$7.74M	Hold	624,288	–	–	0.3%	69
2016 Q2	$6.71M	Hold	624,288	–	–	0.27%	78
2016 Q1	$6.89M	Buy	624,288 +150,000	+32%	+$1.49M	0.29%	71
2015 Q4	$5.79M	Buy	+474,288	New	+$7.39M	0.21%	84

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Tekla Capital Management's AVDL Position: Q1 2021 in Review

Tekla Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2021, closing a stake of 233,612 shares — an estimated $1.56M sold.

Tekla Capital Management first reported a position in AVDL in Q4 2015 and held it in 21 quarters. The position peaked at $7.74M in Q3 2016. 76 funds tracked by Wall St. Rank hold AVDL as of Q1 2021.

Tekla Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 233,612 Avadel Pharmaceuticals shares in Q1 2021, an estimated $1.56M.
Tekla Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2015 and held it in 21 quarters.
Tekla Capital Management's Avadel Pharmaceuticals position peaked at $7.74M in Q3 2016.
76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.